At the AUA 2024 Annual Meeting, Daniel Joyce, MD, of Vanderbilt University Medical Center, and Abhinav Khanna, MD, MPH, of Mayo Clinic, highlight newly presented research examining the utility of a deep learning algorithm for automated renal volume calculation. The algorithm was designed to predict postoperative renal function following partial nephrectomy and radical nephrectomy. ...
Renal Cell Carcinoma Diagnostics
Advertisement
Drs. Joyce and Pierorazio weigh appropriate surveillance versus primary intervention for clinical T1a kidney tumors.
A new study by an international research team has identified new susceptibility regions associated with RCC development risk.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Targeted gene panel testing can serve as an option for patients if syndromic features are present.
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Advertisement
Video Insights
Conferene Coverage
Dr. Spiess highlights prevalence of TERT expression and an increase in TROP-2 mRNA expression levels in PSCC patients.
Dr. Nyame shared highlights from his presentation on PC screening in high-risk groups as part of an AUA plenary session.
Researchers found increased OS and PFS benefits when patients received nivolumab plus gemcitabine.
New findings from the Nure-Combo trial examined the use of ABX with nivolumab followed by RC and adjuvant nivolumab.
Dr. Lerner shares updates from the ENLIGHTED trial and analyses pertaining to NAC for UTUC from the ROBUUST registry.
For patients with clinical node-positive UTUC, NAC may lead to improved outcomes compared with adjuvant chemotherapy.
Advertisement
Section Editor
Daniel Joyce, MDDepartment of Urology | Vanderbilt University Medical Center
Advertisement
Get the latest RCC research straight to your inbox.
